Study Progress Report - National Wilms Tumor Study

A recent update of these findings (12) revised the estimate of CHF at 20 years downwards to 1.2% for patients from NWTS 3-4 who received doxorubicin for primary therapy. The risk was considerably higher for patients with left sided tumors than for those with tumors on the right side. ................
................